SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics reported financial results for Q4 and full year 2025,…

C4 Therapeutics, Inc. · 8-K filed Feb 26, 2026 at 07:09 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 26, 2026 at 07:09 ET

C4 Therapeutics reported financial results for Q4 and full year 2025, highlighted by a 112% YoY increase in quarterly revenue to $11.0 million driven by its collaboration with Merck, reduced R&D and G&A expenses, and a strengthened cash position of $297.1 million following a $125 million equity raise. The company advanced its lead candidate cemsidomide into a Phase 2 trial for multiple myeloma and earned a $2 million milestone from Biogen.

  • Revenue increased 112% YoY in Q4 2025 to $11.0 million, driven by prioritization of a KRAS project under the Merck collaboration
  • Full-year 2025 revenue was $35.9 million, up slightly from $35.6 million in 2024
  • R&D expenses decreased to $25.0 million in Q4 2025 from $32.5 million in Q4 2024 due to completion of the CFT1946 Phase 1 trial
  • G&A expenses decreased to $9.2 million in Q4 2025 from $10.4 million in Q4 2024 due to lower stock-based compensation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access